FBFrançoise Bernerd

Françoise Bernerd

*This is an algorithmically generated author record based on publicly available information.

Françoise Bernerd has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Visible Light-Induced Pigmentation: Exploring Variations Across Skin Phototypes and Ancestries

    by Virginie Piffaut, Pascale Renoux, Stéphane Douezan, Lais Lima, Laudine Bertrand, Françoise Bernerd, Claire Marionnet


  • Open Access

    Decoding Hyperpigmentation from Biological Mechanisms to Actives with Clinically Proven Topical Efficacy: A Narrative Review

    by Christine Duval, Jie Qiu, Emilie Warrick, Peggy Sextius, Isabelle Castiel-Higounenc, Leihong Xiang, Francoise Bernerd, Thierry Passeron

    Hyperpigmentation disorders affect a large proportion of the population, significantly impacting their quality of life and carrying considerable social stigma. This growing global concern results in a strong demand for effective treatments. A rich body of literature proposes numerous active ingredients to solve hyperpigmentation concerns. At the same time, the complex regulation of skin pigmentation is much better understood with increased knowledge on the physiopathology of pigmentary disorders, beyond the sole melanogenesis, including the whole tissue environment of melanocytes. The abundance of mechanistic in vitro and in vivo scientific data makes it challenging for non-expert clinicians to identify the optimal care for patients. The aim of this review is to propose state-of-the-art of topical solutions with actives that have demonstrated conclusive clinical efficacy. It analyzes the different mechanisms involved, including the melanogenesis pathway and others addressing the melanocyte microenvironment. This review first examines the prevention of pigmentary disorders and the importance of a broad-spectrum photoprotection including the whole UV spectrum but also visible light in managing hyperpigmentation. The use of antioxidants to combat oxidative stress and complement photoprotection is also discussed. The following section reviews actives targeting the modulation of melanogenesis. It examines tyrosinase inhibitors, which are still widely used to manage hyperpigmentation problems, as well as new compounds targeting downstream pathways. Other clinically effective interventions include the normalization of epidermal homeostasis and the active restoration of the dermal fibroblastic microenvironment, together with anti-inflammatory agents and those aimed at reducing vascularization impact. Finally, this review highlights the value of combined approaches which have been shown to improve clinical efficacy. This suggests that future research should focus on well-tolerated, multifaceted therapies to effectively treat melanin hyperpigmentary disorders.


  • Gain of Protection Afforded by the Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate (MCE) UVA1 Filter on Pigmentary and Aging Signs: An Outdoor 4‐Week Randomized, Intra‐Individual Comparative Study in 52 Brazilian Women

    by Daiane G. Mercurio, Frederic Flament, Benoit Muller, Francoise Bernerd, Martin Josso, Nathalie Jager‐Lezer, Caroline Delaunay, Thierry Passeron

    Background: Conventional sunscreens shield the skin from ultraviolet (UV) rays up to 370 nm leaving wavelengths between 370 and 400 nm unfiltered despite their potentially harmful biological and clinical effects.Objective: The beneficial effects of methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE) UVA1 filter were explored at 1% in a SPF50 sunscreen under outdoors summer conditions against pigmentation and aging signs compared against a reference SPF50 without the MCE filter.Materials and Methods: A prospective randomized comparative intra‐individual study was conducted in 52 Brazilian women (phototype I–III). A hemiface application was performed for the SPF50 sunscreen with 1% MCE and SPF50 reference without MCE before 1‐h outdoor sunlight exposure, twice daily for 4 weeks. Study endpoint included expert panel grading of pigmentation (3), vascular (1) signs as well as facial skin ageing and assessment of facial skin radiance and skin homogeneity by a naïve panel.Results: Significant differences were reported for all facial signs comparing areas protected with SPF50/MCE and SPF50, respectively: upper lip wrinkles, crow's feet wrinkles, upper lip texture, upper lip pigmentation, vascular abnormalities (all p < 0.0001), texture of the mouth contour (p = 0.001), ptosis of lower face (p = 0.003), lateral facial pigmentation (p = 0.005), and whole face pigmentation (p = 0.01). The evaluations performed by naïve panel showed a significant superiority of the SPF50/MCE product for skin homogeneity (p = 0.043).Conclusion: Overall, this study demonstrates a significant gain of protection with the SPF50 containing 1% MCE in reducing hyperpigmentation, redness and aging signs compared to the same SPF50 sunscreen without MCE, thus supporting the need for an enlarged UVA1 photoprotection.


  • Open Access

    Identification of miR-141 as a Regulator of Epidermal Homeostasis

    by Diane-Lore Vieu, Christelle Golebiewski, Cécile Gastaldi, Aude Foucher, Bernard Mari, Roger Rezzonico, Arnaud Droit, Martine Dumont, Philippe Bastien, Françoise Bernerd, et al.


  • Open Access

    Gain of photoprotection afforded by the cyclic merocyanine UVA1 absorber MCE® in sunscreen formulae: A dose effect in vivo clinical trial

    by Romain de Dormael, Caroline Tricaud, Philippe Bastien, Didier Candau, Angelina Roudot, Françoise Bernerd


  • Open Access

    Induced pluripotent stem cells reprogramming overcomes technical limitations for highly pigmented adult melanocyte amplification and integration in 3D skin model

    by Catherine Cohen, Virginie Flouret, Meenhard Herlyn, Mizuho Fukunaga‐Kalabis, Ling Li, Françoise Bernerd

    Understanding pigmentation regulations taking into account the original skin color type is important to address pigmentary disorders. Biological models including adult melanocytes from different phenotypes allow to perform fine‐tuned explorative studies and support discovery of treatments adapted to populations' skin color. However, technical challenges arise when trying to not only isolate but also amplify melanocytes from highly pigmented adult skin. To bypass the initial isolation and growth of cutaneous melanocytes, we harvested and expanded fibroblasts from light and dark skin donors and reprogrammed them into iPSC, which were then differentiated into melanocytes. The resulting melanocyte populations displayed high purity, genomic stability, and strong proliferative capacity, the latter being a critical parameter for dark skin cells. The iPSC‐derived melanocyte strains expressed lineage‐specific markers and could be successfully integrated into reconstructed skin equivalent models, revealing pigmentation status according to the native phenotype. In both monolayer cultures and 3D skin models, the induced melanocytes demonstrated responsiveness to promelanogenic stimuli. The data demonstrate that the iPSC‐derived melanocytes with high proliferative capacity maintain their pigmentation genotype and phenotypic properties up to a proper integration into 3D skin equivalents, even for highly pigmented cells.


  • Open Access

    Improvement of photoprotection with sunscreen formulas containing the cyclic merocyanine UVA1 absorber MCE: In vivo demonstration under simulated and real sun exposure conditions in three randomised controlled trials

    by Romain de Dormael, Francoise Bernerd, Philippe Bastien, Didier Candau, Angelina Roudot, Caroline Tricaud

    Background: Chronic sun exposure induces skin damage leading to skin ageing and skin colour heterogeneity with hyperpigmented spots. In this process ultra violet A (UVA) rays highly contribute, especially long‐UVA (UVA1) supporting the need for an efficient photoprotection over the whole UV spectrum. A new UVA1 filter, methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE), with a pic of absorption at 385 nm, has been recently approved for use in sunscreen products.Objective: Three randomised clinical studies were performed to evaluate the additional photoprotection afforded by a sunscreen formula containing MCE compared to state‐of‐the‐art sunscreen lacking absorption in the longest UVA1 wavelengths. Two studies were performed on European volunteers with UV‐controlled (UVA1, ultra violet B (UVB) + UVA) exposures and one on Indian volunteers under real sun exposures.Methods: Three intraindividual trials (two randomised UV‐controlled and one real sun) were conducted on a total of 62 healthy subjects with Fitzpatrick III–IV and individual typology angle (ITA°) values between −18° and 35°. The MCE at 2% was formulated in a state‐of‐the‐art sun protection factor 30 sunscreen reference allowing to enlarge the absorption profile up to 400 nm. UV‐induced pigmentation was assessed by colorimetric measures and visual scoring at different time points after a single exposure to UVA1 (Study 1) or repeated exposures to daily UV radiation comprising both UVB and UVA (Study 2) or under real sun (Study 3).Results: Whatever the study exposure condition (UVA1, UVB + UVA, real sun), the level of pigmentation was increased as attested by colorimetric parameters (decreased luminance L* and ITA° values) and visual scorings. In the three studies, the comparison showed higher prevention of hyperpigmentation with the sunscreen enlarged in the longest UVA1 wavelengths with MCE compared to the state‐of‐the‐art sunscreen. No side effects were reported.Conclusions: MCE is a valuable UVA1 filter to improve photoprotection over the entire UV spectrum in state‐of‐the‐art sunscreens and limits the impact of UVA1 rays.


  • Open Access

    Sunscreens with the New MCE Filter Cover the Whole UV Spectrum: Improved UVA1 Photoprotection In Vitro and in a Randomized Controlled Trial

    by Claire Marionnet, Romain de Dormael, Xavier Marat, Angélina Roudot, Julie Gizard, Emilie Planel, Carine Tornier, Christelle Golebiewski, Philippe Bastien, Didier Candau, et al.


  • NK Cell and Fibroblast-Mediated Regulation of Skin Squamous Cell Carcinoma Invasion by CLEC2A Is Compromised in Xeroderma Pigmentosum

    by Maria Gonçalves-Maia, Yannick Gache, Miguel Basante, Estelle Cosson, Emie Salavagione, Margot Muller, Françoise Bernerd, Marie Françoise Avril, Sébastien Schaub, Alain Sarasin, et al.


  • Top Cited Papers
    Open Access

    Sunscreen photoprotection and vitamin D status

    by T. Passeron, R. Bouillon, V. Callender, T. Cestari, T.L. Diepgen, A.C. Green, J.C. van der Pols, B.A. Bernard, F. Ly, F. Bernerd, et al.

    Background Global concern about vitamin D deficiency has fuelled debates on photoprotection and the importance of solar exposure to meet vitamin D requirements. Objectives To review the published evidence to reach a consensus on the influence of photoprotection by sunscreens on vitamin D status, considering other relevant factors. Methods An international panel of 13 experts in endocrinology, dermatology, photobiology, epidemiology and biological anthropology reviewed the literature prior to a 1‐day meeting in June 2017, during which the evidence was discussed. Methods of assessment and determining factors of vitamin D status, and public health perspectives were examined and consequences of sun exposure and the effects of photoprotection were assessed. Results A serum level of ≥ 50 nmol L−1 25(OH)D is a target for all individuals. Broad‐spectrum sunscreens that prevent erythema are unlikely to compromise vitamin D status in healthy populations. Vitamin D screening should be restricted to those at risk of hypovitaminosis, such as patients with photosensitivity disorders, who require rigorous photoprotection. Screening and supplementation are advised for this group. Conclusions Sunscreen use for daily and recreational photoprotection does not compromise vitamin D synthesis, even when applied under optimal conditions. What's already known about this topic? Knowledge of the relationship between solar exposure behaviour, sunscreen use and vitamin D is important for public health but there is confusion about optimal vitamin D status and the safest way to achieve this. Practical recommendations on the potential impact of daily and/or recreational sunscreens on vitamin D status are lacking for healthy people. What does this study add? Judicious use of daily broad‐spectrum sunscreens with high ultraviolet (UV) A protection will not compromise vitamin D status in healthy people. However, photoprotection strategies for patients with photosensitivity disorders that include high sun‐protection factor sunscreens with high UVA protection, along with protective clothing and shade‐seeking behaviour are likely to compromise vitamin D status. Screening for vitamin D status and supplementation are recommended in patients with photosensitivity disorders.